BIOX
Get informed when a big investor buys or sells
+ FollowOvervalued by 2649.2% based on the discounted cash flow analysis.
| Market cap | $26.56 Million |
|---|---|
| Enterprise Value | $254.96 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.82 |
| Beta | 0.39 |
| Outstanding Shares | 63,600,000 |
| P/E Ratio | -0.11 |
|---|---|
| PEG | -0.02 |
| Price to Sales | 0.11 |
| Price to Book Ratio | 0.42 |
| Enterprise Value to Revenue | 0.97 |
| Enterprise Value to EBIT | -20.41 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.95 |
| Debt to Equity | 3.59 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 11,900▼ 6.30% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 14.57%▼ 7.01% |
|---|---|
| Total Invested | $4.11M▼ 77.08% |
| Investors Holding | 31▼ 7.00% |
No data